The oral presentation, titled “The Heparinoid Sevuparin Improves Anemia and Kidney Status in a Mouse Model of Chronic Kidney Disease,” will be delivered on May 27 by Dr. Michela Asperti, senior researcher in Professor Maura Poli’s team at the University of Brescia. The study demonstrates that sevuparin improves anemia and kidney status in a well-established chronic kidney disease (CKD) mouse model.

“We are truly grateful for our longstanding and productive collaboration with Professor Poli and her team, who continue to lead important research in iron regulation and anemia,” said John Öhd, CEO of Modus Therapeutics.

In the presented data, treatment with sevuparin alone in this mouse model resulted in improved hemoglobin levels and suppression of hepcidin – the key regulator of iron metabolism. When administered in combination with erythropoietin (EPO), the standard of care for CKD-related anemia, sevuparin enhanced and sustained the hemoglobin response over a six-week period. Furthermore, positive changes of the treatment on renal status were demonstrated through lowered levels of creatinine and reduced tissue fibrosis.

“These data, along with our previously published results in HemaSphere (December 2024), underscore sevuparin’s therapeutic potential in anemia associated with kidney disease, chronic inflammation and the regulation of hepcidin,” Öhd continued. “They form an important part of the scientific basis for our ongoing Phase II study in patients with CKD and anemia.”

The program for the BioIron Congress is available through this link: https://bioiron.org/docs/meetings/bio2505/schedule.aspx